Waldemar Priebe, Ph.D.

Peer-Reviewed Articles

1. Fokt I, Cybulski M, Skora S, Pajak B, Ziemniak M, Wozniak K, Zielinski R, Priebe W. d-Glucose- and d-mannose-based antimetabolites. Part 4: Facile synthesis of mono- and di-acetates of 2-deoxy-d-glucose prodrugs as potentially useful antimetabolites. Carbohydr Res 531:108861, 2023. e-Pub 2023. PMID: 37356236.
2. Guarnieri JW, Dybas JM, Fazelinia H, Kim MS, Frere J, Zhang Y, Soto Albrecht Y, Murdock DG, Angelin A, Singh LN, Weiss SL, Best SM, Lott MT, Zhang S, Cope H, Zaksas V, Saravia-Butler A, Meydan C, Foox J, Mozsary C, Bram Y, Kidane Y, Priebe W, Emmett MR, Meller R, Demharter S, Stentoft-Hansen V, Salvatore M, Galeano D, Enguita FJ, Grabham P, Trovao NS, Singh U, Haltom J, Heise MT, Moorman NJ, Baxter VK, Madden EA, Taft-Benz SA, Anderson EJ, Sanders WA, Dickmander RJ, Baylin SB, Wurtele ES, Moraes-Vieira PM, Taylor D, Mason CE, Schisler JC, Schwartz RE, Beheshti A, Wallace DC. Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts. Sci Transl Med 15(708):eabq1533, 2023. e-Pub 2023. PMID: 37556555.
3. Hughes EA, Zielinski R, Ray AE, Priebe W, Douglass Junior EF. Development of a Novel Tool To Demystify Drug Distribution at Tissue-Blood Barriers. Chembiochem 24(13):e202200804, 2023. e-Pub 2023. PMID: 36951632.
4. Dempke WCM, Zielinski R, Winkler C, Silberman S, Reuther S, Priebe W. Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?. Eur J Cancer 185:94-104, 2023. e-Pub 2023. PMID: 36966697.
5. Martinez-Castillo M, Altamirano-Mendoza I, Zielinski R, Priebe W, Piña-Barba C, Gutierrez-Reyes G. Collagen matrix scaffolds: Future perspectives for the management of chronic liver diseases. World J Clin Cases 11(6):1224-1235, 2023. PMID: 36926129.
6. Pajak B, Zielinski R, Manning JT, Matejin S, Paessler S, Fokt I, Emmett MR, Priebe W. The Antiviral Effects of 2-Deoxy-D-glucose (2-DG), a Dual D-Glucose and D-Mannose Mimetic, against SARS-CoV-2 and Other Highly Pathogenic Viruses. Molecules 27(18), 2022. e-Pub 2022. PMID: 36144664.
7. Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien B, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol 11(2):CNS87, 2022. e-Pub 2022. PMID: 35575067.
8. Ziemniak M, Pawledzio S, Zawadzka-Kazmierczuk A, Dominiak PM, Trzybinski D, Kozminski W, Zielinski R, Fokt I, Priebe W, Wozniak K, Pajak B. X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-d-glucose in solid state and solution. RSC Adv 12(14):8345-8360, 2022. e-Pub 2022. PMID: 35424802.
9. Ziemniak M, Pawledzio S, Zawadzka-Kazimierczuk A, Dominiak PM, Trzybinski D, Kozminski W, Zielinski R, Fokt I, Priebe W, Wozniak K, Pajak B. Correction: X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-d-glucose in solid state and solution. RSC Adv 12(17):10306, 2022. e-Pub 2022. PMID: 35427095.
10. Guarnieri JW, Dybas JM, Fazelinia H, Kim MS, Frere J, Zhang Y, Albrecht YS, Murdock DG, Angelin A, Singh LN, Weiss SL, Best SM, Lott MT, Cope H, Zaksas V, Saravia-Butler A, Meydan C, Foox J, Mozsary C, Kidane YH, Priebe W, Emmett MR, Meller R, Singh U, Bram Y, tenOever BR, Heise MT, Moorman NJ, Madden EA, Taft-Benz SA, Anderson EJ, Sanders WA, Dickmander RJ, Baxter VK, Baylin SB, Wurtele ES, Moraes-Vieira PM, Taylor D, Mason CE, Schisler JC, Schwartz RE, Beheshti A, Wallace DC. Targeted Down Regulation Of Core Mitochondrial Genes During SARS-CoV-2 Infection. bioRxiv, 2022. e-Pub 2022. PMID: 35233572.
11. Pajak B, Siwiak-Niedbalska E, Jaskiewicz A, Soltyka M, Zielinski R, Domoradzki T, Fokt I, Skóra S, Priebe W*. Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model. Biomedicines 9(12), 2021. e-Pub 2021. PMID: 34944565.
12. McDonald JT, Enguita FJ, Taylor D, Griffin RJ, Priebe W, Emmett MR, Sajadi MM, Harris AD, Clement J, Dybas JM, Aykin-Burns N, Guarnieri JW, Singh LN, Grabham P, Baylin SB, Yousey A, Pearson AN, Corry PM, Saravia-Butler A, Aunins TR, Sharma S, Nagpal P, Meydan C, Foox J, Mozsary C, Cerqueira B, Zaksas V, Singh U, Wurtele ES, Costes SV, Davanzo GG, Galeano D, Paccanaro A, Meinig SL, Hagan RS, Bowman NM, UNC COVID-19 Pathobiology Consortium, Wolfgang MC, Altinok S, Sapoval N, Treangen TJ, Moraes-Vieira PM, Vanderburg C, Wallace DC, Schisler JC, Mason CE, Chatterjee A, Meller R, Beheshti A. Role of miR-2392 in driving SARS-CoV-2 infection. Cell Rep 37(3):109839, 2021. e-Pub 2021. PMID: 34624208.
13. Kalinowska M, Golebiewska E, Swiderski G, Meczynska-Wielgosz S, Lewandowska H, Pietryczuk A, Cudowski A, Astel A, Swislocka R, Samsonowicz M, Zlowodzka AB, Priebe W, Lewandowski W. Plant-Derived and Dietary Hydroxybenzoic Acids-A Comprehensive Study of Structural, Anti-/Pro-Oxidant, Lipophilic, Antimicrobial, and Cytotoxic Activity in MDA-MB-231 and MCF-7 Cell Lines. Nutrients 13(9), 2021. e-Pub 2021. PMID: 34578985.
14. McDonald JT, Enguita FJ, Taylor D, Griffin RJ, Priebe W, Emmett MR, Sajadi MM, Harris AD, Clement J, Dybas JM, Aykin-Burns N, Guarnieri JW, Singh LN, Grabham P, Baylin SB, Yousey A, Pearson AN, Corry PM, Saravia-Butler A, Aunins TR, Sharma S, Nagpal P, Meydan C, Foox J, Mozsary C, Cerqueira B, Zaksas V, Singh U, Wurtele ES, Costes SV, Davanzo GG, Galeano D, Paccanaro A, Meinig SL, Hagan RS, Bowman NM, UNC COVID-19 Pathobiology Consortium, Wolfgang MC, Altinok S, Sapoval N, Treangen TJ, Moraes-Vieira PM, Vanderburg C, Wallace DC, Schisler J, Mason CE, Chatterjee A, Meller R, Beheshti A. The Great Deceiver: miR-2392's Hidden Role in Driving SARS-CoV-2 Infection. bioRxiv, 2021. e-Pub 2021. PMID: 33948587.
15. Ziemniak M, Zawadzka-Kazimierczuk A, Pawledzio S, Malinska M, Soltyka M, Trzybinski D, Kozminski W, Skora S, Zielinski R, Fokt I, Priebe W, Wozniak K, Pajak B. Experimental and Computational Studies on Structure and Energetic Properties of Halogen Derivatives of 2-Deoxy-D-Glucose. Int J Mol Sci 22(7), 2021. e-Pub 2021. PMID: 33918425.
16. Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab 3(1):122, 2021. PMID: 33340032.
17. Silberman S., Hsu S. Muczyczenko Z., Picker D., Sipowicz M., Zak E., Buczynska A., Olejniczak M. Priebe W*. Design and initiation of pivotal studies for Berubicin, a novel potent topoisomerase II poison for the treatment of recurrent glioblastoma multiforme (GBM). Neuro-Oncol 23:193, 2021.
18. Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab 2(12):1413-1426, 2020. e-Pub 2020. PMID: 33230295.
19. Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong LY, Fuller GN, DeGroot J, Sulman EP, Heimberger AB. Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy. Clin Cancer Res 26(18):4983-4994, 2020. e-Pub 2020. PMID: 32605912.
20. Sharma P, Roberts C, Herpai D, Fokt ID, Priebe W, Debinski W. Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals (Basel) 13(4), 2020. e-Pub 2020. PMID: 32340173.
21. Pajak B, Siwiak E, Soltyka M, Priebe A, Zielinski R, Fokt I, Ziemniak M, Jaskiewicz A, Borowski R, Domoradzki T, Priebe W*. 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents. Int J Mol Sci 1(1), 2019. e-Pub 2019. PMID: 31905745.
22. Golonko A, Lewandowska H, Swislocka R, Jasinska UT, Priebe W, Lewandowski W. Curcumin as tyrosine kinase inhibitor in cancer treatment. Eur J Med Chem 181:111512, 2019. e-Pub 2019. PMID: 31404861.
23. Michel KA, Zielinski R, Walker CM, Le Roux L, Priebe W||B, Bankson JA, Schellingerhout D. Hyperpolarized Pyruvate MR Spectroscopy Depicts Glycolytic Inhibition in a Mouse Model of Glioma. Radiology 293(1):182919, 2019. e-Pub 2019. PMID: 31385757.
24. Rios Perez MV, Roife D, Dai B, Pratt M, Dobrowolski R, Kang Y, Li X, Augustine JJ, Zielinski R, Priebe W, Fleming JB. Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models. Surg Open Sci 1(2):Pages 56-63, 2019. e-Pub 2019. PMID: 33981979.
25. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of Brain Metastases: Prioritization of Therapeutic Targets. Int J Cancer 143(11):3019-3026, 2018. e-Pub 2018. PMID: 29923182.
26. Olbryt M, Rusin A, Fokt I, Habryka A, Tudrej P, Student S, Sochanik A, Zielinski R, Priebe W*. Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation. Invest New Drugs 35(5):545-555, 2017. e-Pub 2017. PMID: 28417283.
27. Sonawane P, Choi YA, Pandya H, Herpai DM, Fokt I, Priebe W, Debinski W. Novel Molecular Multilevel Targeted Antitumor Agents. Cancer Transl Med 3(3):69-79, 2017. e-Pub 2017. PMID: 28825042.
28. Santoro M, Menegaz BA, Lamhamedi-Cherradi SE, Molina ER, Wu D, Priebe W* Ludwig JA, Mikos AG. MODELING STROMA-INDUCED DRUG RESISTANCE IN A TISSUE-ENGINEERED TUMOR MODEL OF EWING SARCOMA. Tissue Eng Part A 23(1-2):80-89, 2017. e-Pub 2016. PMID: 27923328.
29. Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst 108(12), 2016. e-Pub 2016. PMID: 27576731.
30. Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bögler O. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med 14(1):46, 2016. e-Pub 2016. PMID: 26861698.
31. Priebe W. Obituary: Derek Horton (1933-2015). Glycoconj J 32(8):557-8, 2015. PMID: 26498188.
32. Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF. Mesenchymal Stem Cells Isolated from Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells 33(8):2400-15, 2015. e-Pub 2015. PMID: 25966666.
33. Malinska M, Fokt I, Priebe W, Wozniak K,. Bromine Atom Interactions in Biologically Active Acrylamide Derivatives. Crystal Growth and Design 15(6):2632–2642, 2015.
34. Mansilla S, Vizcaíno C, Rodríguez-Sánchez MA, Priebe W, Portugal J. Autophagy modulates the effects of bis-anthracycline WP631 on p53-deficient prostate cancer cells. J Cell Mol Med 19(4):786-798, 2015. e-Pub 2015. PMID: 25689150.
35. Lee HT, Xue J, Chou PC, Zhou A, Yang P, Conrad CA, Aldape KD, Priebe W, Patterson C, Sawaya R, Xie K, Huang S. Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget 6(12):10016-29, 2015. PMID: 25881542.
36. Kong LY, Wei J, Haider AS, Liebelt BD, Ling X, Conrad CA, Fuller GN, Levine NB, Priebe W, Sawaya R, Heimberger AB. Therapeutic targets in subependymoma. J Neuroimmunol 277(1-2):168-175, 2014. e-Pub 2014. PMID: 25465288.
37. Kalinowska M, Bielawska A, Lewandowska-Siwkiewicz H, Priebe W, Lewandowski W. Apples: Content of phenolic compounds vs. variety, part of apple and cultivation model, extraction of phenolic compounds, biological properties. Plant Physiol Biochem 84C:169-188. e-Pub 2014. PMID: 25282014.
38. Emmett MR, Kroes RA, Moskal JR, Conrad CA, Priebe W, Laezza F, Meyer-Baese A, Nilsson CL. Integrative Biological Analysis for Neuropsychopharmacology. Neuropsychopharmacology 39(1):5-23, 2014. e-Pub 2013. PMID: 23800968.
39. Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W, Giraud AS. Inhibition of the JAK2/STAT3 Pathway Reduces Gastric Cancer Growth In Vitro and In Vivo. PLoS One 9(5):e95993, 2014. e-Pub 2014. PMID: 24804649.
40. Mielecki M, Krawiec K, Kiburu I, Grzelak K, Zagórski W, Kierdaszuk B, Kowa K, Fokt I, Szymanski S, Swierk P, Szeja W, Priebe W, Lesyng B, LaRonde-LeBlanc N. Development of novel molecular probes of the Rio1 atypical protein kinase. Biochim Biophys Acta 1834(7):1292-301, 2013. e-Pub 2013. PMID: 23523885.
41. Fokt I, Skora S, Conrad C, Madden T, Emmett M, Priebe W. D-Glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated D-glucose, D-mannose, and 2-deoxy-D-glucose. Carbohydr Res 368:111-9, 2013. e-Pub 2012. PMID: 23376241.
42. Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, Yao J, Priebe W, Colman H, Elferink LA, Bogler O. Regulation of HGF expression by ?EGFR-mediated c-Met activation in glioblastoma cells. Neoplasia 15(1):73-84, 2013. PMID: 23359207.
43. Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol 14(9):1136-45, 2012. e-Pub 2012. PMID: 22753228.
44. Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer 30(7):8-17, 2012. e-Pub 2011. PMID: 21792892.
45. Swiatek-Machado K, Mieczkowski J, Ellert-Miklaszewska A, Swierk P, Fokt I, Szymanski S, Skora S, Szeja W, Grynkiewicz G, Lesyng B, Priebe W, Kaminska B. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biol Ther 13(8):657-70, 2012. e-Pub 2012. PMID: 22555804.
46. Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol 107(3):487-501, 2012. e-Pub 2012. PMID: 22249692.
47. Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, Showalter HD, Talpaz M, Donato NJ. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cell Signal 23(12):2076-85, 2011. e-Pub 2011. PMID: 21855629.
48. Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC, Priebe W*. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol 68(4):1033-44, 2011. e-Pub 2011. PMID: 21340606.
49. Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20(3):384-99, 2011. PMID: 21907928.
50. Mansilla S, Priebe W, Portugal J. Changes in gene expression induced by Sp1 knockdown differ from those caused by challenging Sp1 binding to gene promoters. Biochim Biophys Acta 1809(7):327-36, 2011. e-Pub 2011. PMID: 21684359.
51. Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W, Myers JN. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 117(13):2926-38, 2011. e-Pub 2011. PMID: 21692052.
52. Pastuch G, Wandzik I, Szeja W, Grynkiewicz G, Ramza J, Priebe W, Pucko W. New synthesis of O- and S-glycosyl derivatives of 2-chloro-3-cyano-5-nitropyridine. Heterocyclic Communications 7(4):317-322, 2011. e-Pub 2011.
53. Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, Priebe W, Arlinghaus R. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25(3):463-72, 2011. e-Pub 2010. PMID: 21183952.
54. Yan H, Chen X, Zhang Q, Qin J, Li H, Liu C, Calhoun-Davis T, Coletta LD, Klostergaard J, Fokt I, Skora S, Priebe W, Bi Y, Tang DG. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. PLoS One 6(9):e24397, 2011. e-Pub 2011. PMID: 21935404.
55. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 12(11):1113-25, 2010. e-Pub 2010. PMID: 20667896.
56. Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther 9(7):2026-36, 2010. e-Pub 2010. PMID: 20606045.
57. Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res 16(9):2550-61, 2010. e-Pub 2010. PMID: 20388845.
58. He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR, Ji Y, Colman H, Priebe W, Lang FF, Conrad CA. Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. J Proteome Res 9(5):2098-108, 2010. PMID: 20199106.
59. Priebe W. Glycals: New Chemistry and Synthesis of Novel Inhibitors of Glycolysis. 17th Annual New Orleans Carbohydrate Symposium, 2010.
60. Nilsson CL, Dillon R, Devakumar A, Shi SD, Greig M, Rogers JC, Krastins B, Rosenblatt M, Kilmer G, Major M, Kaboord BJ, Sarracino D, Rezai T, Prakash A, Lopez M, Ji Y, Priebe W, Lang FF, Colman H, Conrad CA. Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res 9(1):430-43, 2010. PMID: 19899826.
61. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 9(1):67-78, 2010. e-Pub 2010. PMID: 20053772.
62. He H, Nilsson C, Emmett M, Wang X, Marshall A, Kroes R, Moskal J, Ji Y, Priebe W, Colman H, Lang F, Conrad C. Applying FT-ICR MS in a Glycomics Approach Toward Understanding Glioblastoma Cancer Stem Cell Differentiation. Glycobiology 19(11):1365, 2009.
63. Fokt I, Szymanski S, Skora S, Cybulski M, Madden T, Priebe W*. D-Glucose- and D-mannose-based antimetabolites. Part 2. Facile synthesis of 2-deoxy-2-halo-D-glucoses and -D-mannoses. Carbohydr Res 344(12):1464-1473, 2009. e-Pub 2009. PMID: 19625015.
64. Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 58(7):1023-32, 2009. e-Pub 2008. PMID: 19002459.
65. Swiatek-Machado K, Ellert-Miklaszewska A, Szeja W, Priebe W, Grynkiewicz G, Lesyng B, Kaminska B. Evaluation of antitumor activity of novel inhibitors of JAK/STAT3 pathway in glioma cells. FEBS Journal 276(S1):392, 2009.
66. Gao H, Priebe W, Glod J, Banerjee D. Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium. Stem Cells 27(4):857-865, 2009. PMID: 19350687.
67. Heimberger AB, Kong LY, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Wei J, Qiao W, Schmittling RJ, Archer GE, Sampson JH, Hiraoka N, Priebe W, Fuller GN, Sawaya R. The Role of Tregs in Human Glioma Patients and their Inhibition with a Novel STAT-3 Inhibitor. Clin Neurosurg 56(6):98-106, 2009. PMID: 20214040.
68. Kupferman ME, Jayakumar A, Zhou G, Xie T, Dakak-Yazici Y, Zhao M, Ju J, Mandal M, Jasser S, Madden T, Myers JN, Priebe W*. Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol 8(2):117-27, 2009. PMID: 20192118.
69. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14(24):8228-35, 2008. PMID: 19088040.
70. Korchowiec J, Korchowiec B, Priebe W, Rogalska E. DFT study on the selectivity of complexation of metal cations with a dioxadithia crown ether ligand. J Phys Chem A 112(51):13633-40, 2008. PMID: 19055400.
71. van Schalkwyk DA, Priebe W, Saliba KJ. The inhibitory effect of 2-halo derivatives of D-glucose on glycolysis and on the proliferation of the human malaria parasite Plasmodium falciparum. J Pharmacol Exp Ther 327(2):511-7, 2008. e-Pub 2008. PMID: 18713952.
72. Heimberger AB, Priebe W*. Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers. Recent Pat CNS Drug Discov 3(3):179-88, 2008. PMID: 18991807.
73. Corvis Y, Korchowiec B, Korchowiec J, Badis M, Mironiuk-Puchalska E, Fokt I, Priebe W, Rogalska E. Complexation of metal ions in Langmuir films formed with two amphiphilic dioxadithia crown ethers. J Phys Chem B 112(35):10953-63, 2008. e-Pub 2008. PMID: 18698707.
74. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14(18):5759-68, 2008. PMID: 18794085.
75. Bednarek E, Sitkowski J, Kawecki R, Kozerski L, Bocian W, Pazderski L, Priebe W*. Structure and dynamics of methyl cis-3,4-diamino-2,3,4,6-tetradeoxy-alpha-l-lyxo-hexopyranoside complexes with PtCl(2) and PdCl(2), by (1)H, (2)H, (13)C, (15)N and (195)Pt NMR spectroscopy in DMSO, CD(3)CN and H(2)O. Dalton Trans N/A(31):4129-37, 2008. e-Pub 2008. PMID: 18688431.
76. Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 14(3):788-796, 2008. PMID: 18245540.
77. Gruber BM, Anuszewska EL, Bubko I, Kasprzycka-Guttman T, Misiewicz I, Skupinska K, Fokt I, Priebe W*. NF kappa B activation and drug sensitivity in human neoplastic cells treated with anthracyclines. Acta Poloniae Pharmaceutica 65(2):267-71, 2008. PMID: 18666436.
78. Tamura A, Onishi Y, An R, Koshiba S, Wakabayashi K, Hoshijima K, Priebe W, Yoshida T, Kometani S, Matsubara T, Mikuriya K, Ishikawa T. In Vitro Evaluation of Photosensitivity Risk related to Genetic Polymorphisms of Human ABC Transporter ABCG2 and Inhibition by Drugs. Drug Metab Pharmacokinet 22(6):428-440, 2007. PMID: 18159130.
79. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 67(23):11291-9, 2007. PMID: 18056455.
80. Zheng M, Priebe W, Walch ET, Roth KG, Han M, Tang CH, Lee S, Poindexter NJ, Fokt I, Grimm EA. WP760, a melanoma selective drug. Cancer Chemother Pharmacol 60(5):625-33, 2007. e-Pub 2006. PMID: 17195067.
81. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67(20):9630-6, 2007. PMID: 17942891.
82. Bidwell GL, Davis AN, Fokt I, Priebe W, Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New Drugs 25(4):313-26, 2007. e-Pub 2007. PMID: 17483874.
83. Gruber BM, Anuszewska EL, Bubko I, Gozdzik A, Fokt I, Priebe W. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz) 55(3):193-8, 2007. e-Pub 2007. PMID: 17557149.
84. Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109(8):3470-3478, 2007. e-Pub 2007. PMID: 17202319.
85. Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest New Drugs 25(2):115-122, 2007. e-Pub 2006. PMID: 17072745.
86. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26(17):2435-2444, 2007. e-Pub 2006. PMID: 17043651.
87. Mansilla S, Rojas M, Bataller M, Priebe W, Portugal J. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochem Pharmacol 73(7):934-42, 2007. e-Pub 2006. PMID: 17217917.
88. Bidwell GL, Fokt I, Priebe W, Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol 73(5):620-31, 2007. e-Pub 2006. PMID: 17161827.
89. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67(2):684-694, 2007. PMID: 17234779.
90. Schroeder C, Fokt I, Johansen M, Rhea R, Allen TL, Madden T, |Priebe W*. WP760, a new DNA-binding agent with unique melanoma selectivity. Molecular Cancer Therapeutics 6(12):3407S-3407S, 2007.
91. Lampidis TJ, Kurtoglu M, Maher JC, Liu H, Krishan A, Sheft V, Szymanski S, Fokt I, Rudnicki WR, Ginalski K, Lesyng B, Priebe W*. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemother Pharmacol 58(6):725-34, 2006. e-Pub 2006. PMID: 16555088.
92. Mansilla S, Priebe W, Portugal J. Transcriptional changes facilitate mitotic catastrophe in tumor cells that contain functional p53. Eur J Pharmacol 540(1-3):34-45, 2006. e-Pub 2006. PMID: 16735036.
93. Anuszewska E, Chlopkiewicz B, Gruber B, Marczewska J, Priebe W, Skurzak H. Estimation of DNA damage and cytotoxicity of anthracycline analogs in human melanoma cells on early and late passages. Acta Pol Pharm 63(4):321-4, 2006. PMID: 17203872.
94. Mansilla S, Priebe W, Portugal J. Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle 5(1):53-60, 2006. e-Pub 2006. PMID: 16319532.
95. Gruber BM, Anuszewska EL, Roman I, Gozdzik A, Priebe W, Fokt I. Topoisomerase II alpha expression and cytotoxicity of anthracyclines in human neoplastic cells. Acta Pol Pharm 63(1):15-8, 2006. PMID: 17515324.
96. Portugal J, Cashman DJ, Trent JO, Ferrer-Miralles N, Przewloka T, Fokt I, Priebe W, Chaires JB. A new bisintercalating anthracycline with picomolar DNA binding affinity. J Med Chem 48(26):8209-19, 2005. PMID: 16366602.
97. Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res 25(3B):1841-50, 2005. PMID: 16158916.
98. Gruber BM, Anuszewska EL, Bubko I, Gozdzik A, Priebe W, Fokt I. Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells. Anticancer Res 25(3B):2193-8, 2005. PMID: 16158963.
99. Fokt I, Grynkiewicz G, Skibicki P, Przewloka T, Priebe W*. New Strategies Towards Synthesis of Doxorubicin Analogs. Polish J. Chem 79:349-359, 2005.
100. Frelek J, Kaminska A, Pakulski Z, Szmigielski R, Priebe W*. Chirality Probing of Chlorotetrabutyratodiruthenium (II,III) Complexes with vic-Amino Alcohols by Circular Dichroism Spectroscopy. Polish J. Chem 79:387-399, 2005.
101. Grynkiewicz G, Fokt I, Skibicki P, Przewloka T, Szeja W, Priebe W,. Synthesis of 1- O-Silylated 3-Azido- and 3-N-Trifluoroacetamido-2,3,6-trideoxy-L-arabino and L-lyxo-hexapyranoses, Convenient Glycosyl Donors for Preparation of Anthracyclic Antibiotics and Related DNA-Binding Agents. Polish J. Chem 79:335-347, 2005.
102. Fanale MA, Liu Y, McKenzie TS, Fokt I, Priebe W*. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. Journal of Clinical Oncology 23(16):155S-155S part 1Suppl. S, 2005.
103. Nair RR, Wang H, Jamaluddin MS, Fokt I, Priebe W, Boyd DD. A bisanthracycline (WP631) represses uPAR gene expression and cell migration of RKO colon cancer cells by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region. Oncol Res 15(5):265-79, 2005. PMID: 16261846.
104. Fox KR, Webster R, Phelps RJ, Fokt I, Priebe W. Sequence selective binding of bis-daunorubicin WP631 to DNA. Eur J Biochem 271(17):3556-66, 2004. PMID: 15317591.
105. Mansilla S, Priebe W, Portugal J. Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes. Biochemistry 43(23):7584-92, 2004. PMID: 15182200.
106. Pozarowski P, Huang X, Gong RW, Priebe W, Darzynkiewicz Z. Simple, semiautomatic assay of cytostatic and cytotoxic effects of antitumor drugs by laser scanning cytometry: effects of the bis-intercalator WP631 on growth and cell cycle of T-24 cells. Cytometry A 57(2):113-9, 2004. PMID: 14750133.
107. Gruber BM, Anuszewska EL, Priebe W. The effect of new anthracycline derivatives on the induction of apoptotic processes in human neoplastic cells. Folia Histochem Cytobiol 42(2):127-30, 2004. PMID: 15253137.
108. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64(1):31-4, 2004. PMID: 14729604.
109. Samochocka K, Fokt I, Anulewicz-Ostrowska R, Przewloka T, Mazurek AP, Fuks L, Lewandowski W, Kozerski L, Bocian W, Bednarek E, Lewandowska H, Sitkowski J Priebe W. Platinum(II) and Palladium(II) Complexes with Methyl 3,4-diamino-2,3,4,6 tetradeoxy-a-L-lyxo-hexopyranoside. Dalton Trans:2177-83, 2003.
110. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 21(6A):3777-84, 2001. PMID: 11911247.
111. Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 40(18):5542-7, 2001. PMID: 11331019.
112. Janota-Bassalik L, Pietraszek A, Priebe W*. Studies Upon Resistance Factors in the Mammary Gland. Prace i Materialy Zootechniczne 2:59-72, 1973.
113. Janota-Bassalik L, Zajac M, Pietraszek A, Priebe W*. Ecological patterns of udder infection. Acta Microbiol Pol B 4:245-8, 1972. PMID: 4566375.

Invited Articles

1. Priebe, W. Anthracycline Chemistry and Biology 1: Biological Occurrence and Biosynthesis, Synthesis and Chemistry. Journal of the American Chemical Society 131(23):8335, 2009.

Other Articles

1. Lin YH, Santani N, Hammoudi N, Ackroyd J, Khadka S, Yan V, Georgiou D, Sun Y, Zielinski R, Tran T, Pando S, Wang X, Maxwell D, Peng Z, Pisaneschi F, Mandal P, Leonard P, Xu Q, Wu Q, Jiang Y, Czako B, Kang Z, Asara J, Priebe W, Bornmann W, Marszalek J, DePinho R, Muller F Eradication of ENO1-deleted Glioblastoma through Collateral Lethality. bioRxiv, 2018.
2. Witczak ZJ, Priebe W* Carbohydrate chemistry. Current Organic Chemistry 12(12):972, 2008. PMID: 13852728.

Abstracts

1. Kang Y, Zielinski R, Cardenas-Zuniga R, Venugopal R, Felix E, Grela K, Skora S, Nguyen V, Guzman V, Damian J Grybowski, Peng S, Fokt I, Priebe W*. Topoisomerase IIα, a Therapeutically Unexplored Target in PDAC: High in Vivo Efficacy of Annamycin, an Organotropic TOP2A Poison. The 7th JCA-AACR Special Joint Conference Secretariat, 2022.
2. Zielinski R, Grela K, Cardenas-Zuniga R, Skora S, Fokt I, Felix E, Grybowski D, Priebe* W. New approach to target metastatic colorectal cancer organotropism with L-Annamycin. Annual AACR meeting, New Orleans, 2022, 2022.
3. Zielinski R., Grela K., Cardenas-Zuniga R, Poimenidou M., Remiszewski M., Felix E., Fokt I., Skora S., Priebe W.*. WP1874, a highly potent unique DNA binding agent with enhanced CNS uptake. Society of Neuro-Oncology 26th Annual Scientific Meeting, Nov 18-21, 2021 23(6):181, 2021.
4. Zielinski R., Grela K., Cardenas-Zuniga R., Fokt I, Venugopal R, Skora S., Poimenidou M., Lamhamedi Cherradi S-E., Ludwig J. A., Priebe W.*. Targeting sarcoma pulmonary metastases with annamycin. CTOS 2021 Annual Meeting, Nov 10-13, 2021, 2021.
5. Zielinski R, Grela K, Cardenas-Zuniga R, Skora S, Fokt I, Poimenidou M, Eddine Lamhamedi-Cherradi S, Ludwig J, Priebe W*. Annamycin, a novel non-cardiotoxic anthracycline with high activity against sarcomas metastatic to lungs. Molecular Targets and Cancer Therapeutics 20(12), 2021.
6. Zielinski R, Poimenidou M , Khuong M, Grela K, Cardenas-Zuniga R, Skora S, Fokt I, Gagea M, Swain J, Zhou S, Priebe W*. Ketogenic diet (KD) and targeting Warburg effect: Apparent toxicity of KD combination with 2-deoxy-D-glucose. AACR-NCI-EORTC 20(12), 2021.
7. Kang Y, Zielinski R, Cardenas Zuniga R, Venugopal R, Poimenidou M, Remiszewski M, Peng S, Felix E, GrelaK, Skora S, Nguyen V, Fokt I, Priebe W*. Abstract PO-066: High uptake, retention, and in vivo activity of L-Annamycin in pancreatic cancer models 81(22), 2021.
8. Z T, Zielinski R, Grela K, Cardenas-Zuniga R, Skora S, Fokt I, Zal M. A., Andreeff M, Gil L, Shephard R, Priebe, W*. High Efficacy of Liposomal Annamycin (L-ANN) in Combination with Cytarabine in Syngeneic p53-Null AML Mouse Model. Blood 136, 2020.
9. Zielinski R, Grela K, Skora S, Fokt I, Sander M, Didluch A, Priebe W*. Liposomal Annamycin Inhibition of Lung Localized Breast Cancer. San Antonio Breast Cancer Symposium (SABC), 2020.
10. Zielinski R, Grela K, Skora S, Jacamo R, Fokt I, Sanders M, Remiszewski M, Felix E, Shanmugasundaram M, Zal MA, Andreeff M, Priebe W, Zal T. Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model. American Society of Hematology (ASH), 2019.
11. Zielinski R, Zal T, Grela K, Skora S, Fokt I, Sanders M, Remiszewski M, Felix E, Shanmugasundaram M, Priebe W*||B. Dose and Schedule-Dependent Efficacy of Liposomal Annamycin in Pre-clinical Models of Acute Myeloid Leukemia. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. e-Pub 2019.
12. Gil L, Shepard R. C., Silberman S. L., Zak E. M., Priebe W*. Clinical Efficacy of L-Annamycin, a Liposomal Formulated Non-Cross-Resistant and Non-Cardiotoxic Anthracycline in Relapsed/Refractory AML Patients. Blood 134(1), 2019.
13. Sokolowska-Wojdylo M., Blazewicz I., Olszweska B., Zak E. M., Klemp W., Silberman S. L., Priebe, W*. A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Stage I, II or III Mycosis Fungoides (MF). Blood 134, 2019.
14. Ott M, Hashimoto Y, Marisetty A, Wei J, Zamler D, Leu JS, Kong LY, Fuller G, de Groot J, Priebe W, Sulman E, Heimberger A. Immunological reprogramming in the CNS tumor microenvironment and therapeutic efficacy of radiotherapy with STAT3 blockade. Society for Neuro-Oncology's Conference on Brain Metastases. e-Pub 2019.
15. Ott M, Hashimoto Y, Marisetty A, Wei J, Zamler D, Leu JS, Kong LY, Zhou S, Fuller G, de Groot J, Priebe W, Sulman E, Heimberger A. mlti-01.immunological reprogramming in the cns tumor microenvironment and therapeutic efficacy of radiotherapy with stat3 blockade. Neuro-Oncology Advances(Supplement_1):i14-i14, 2019.
16. Zielinski R, Fokt I, Skora S, Felix E, Grela K, Arumugam J, Venugopal R, Ai M, Hartley G, Curran M, Priebe W*. Abstract 4799: Inhibition of STAT3 in pancreatic ductal adenocarcinoma and immunotherapeutic implications. Cancer Research 79(13), 2019.
17. Priebe W, Zielinski, R, Fokt I, Felix E, Aramugam J, Venugopal R, Khuong M, Krasinski M, Skora S,. Design and evaluation of WP1122, an inhibitor of glycolysis with increased CNS uptake. Proceedings: 23rd Annual Meeting and Education Day, New Orleans, LA, November 15-18, 2018 20(6):86. e-Pub 2018.
18. Hirak Basu, Nathaniel Wilganowski, Jessica Lieblich, Grace Wu, Izabela Fokt, Sumankalai Ramachandran, Jiaquin Yu, Mark Titus, Waldemar P, David J. Beebe and George Wilding. Abstract B091: Small-molecule inhibitors targeting a specific metabolic pathway for precision therapy of advanced castrate-resistant prostate cancer. Cancer Research 78(16), 2018.
19. Zielinski R, Tworowska I, Skora S, Rusin A, Venugopal R, Arumugam J, Fokt I, Kang Y, Fleming J, Huang Y, Herpai D, Debinski W, Priebe W*. Targeting IL-13RA2 in melanoma and pancreatic cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. (#1927) 78(13):Supplement, 2018.
20. Basu H, Wilgonowski N, Lieblich J, Wu G, Fokt I, Ramachandran S, Yu J, Titus M, Priebe W, Beebe D, Wilding G. A metabolic pathway targeted inhibitor for precision therapy of castrate-resistant prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3846 78(13):Supplement, 2018.
21. Gue C, Fokt I, Fahrenholtz S, Layman R, Priebe W, Cressman E. Alternatives to ethiodized oil in IR research: From biodiesel to radiopaque oily embolic agent. Proceedings: SIR Annual Scientific Meeting, 2018.
22. Ferguson S, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz M, Piccioni D, Suyun H, Davies M, Glitza I, Heymach J, Zhang J, ibrahim N, de Groot J, McCarty J, O'brien B, Sawaya R, Verhaak R, Reddy S, Priebe W, Spetzler D, Heimberger A. CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. Neuro-Oncology, 2017.
23. Zielinski R, Fokt I, Felix E, Khuong M, Krasinski M, Venugopal R, Arumugam J, Skora S, Priebe W*. Preclinical evaluation of WP1122, a 2-DG prodrug and inhibitor of glycolysis. Proceedings: Symposia on Cancer Research 2017 Cancer Metabolism, 2017.
24. Fokt I, Skora S, Cybulski M, Zielinski R, Nguyen V, Felix E, Priebe W*. Design, synthesis, and evaluation of 2-DG prodrugs and potentially useful in vivo inhibitors of glycolysis. Proceedings: Symposia on Cancer Research 2017 Cancer Metabolism, 2017.
25. Michel, K., R. Zielinski, C. Walker, D. Schellingerhout, W. Priebe, J. Bankson. Assessing the Efficacy of a Novel Glycolytic Inhibitor, WP1122, by Non-Invasive In Vivo Hyperpolarized Pyruvate MR Spectroscopy. Proceedings: Symposia on Cancer Research 2017 Cancer Metabolism, 2017.
26. Priebe W, Fokt I, Cybulski M, Conrad C, Madden T,Zielinski R, Rusin A. Latentiation of 2-Deoxy-D-glucose. European Journal of Cancer, Proceedings: 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Munich, Germany; Nov 29- Dec 2, 2016 68(Supplement 1), 2016. e-Pub 2016.
27. Zielinski R,Fokt I, Rusin A, Skora S, Priebe W*. 2-Deoxy-2-halo-D-glucose derivatives inhibition of glycolysis in pancreatic cancer. Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA (#50) 76(14 Supplement). e-Pub 2016.
28. Priebe W. Exploring carbohydrate metabolism to target cancer: Derek Horton’s inspiration. Proceedings: 28th International Carbohydrate Symposium (ICS), New Orleans, LA, July 17-21, 2016 (#382). e-Pub 2016.
29. Fokt I, Cybulski M, Skora S, Priebe W*. Synthesis of selectively acetylated 2-deoxy-D-glucoses, potential agents for treatment. Proceedings: 28th International Carbohydrate Symposium (ICS), New Orleans, LA, July 17-21, 2016 (#46). e-Pub 2016.
30. Priebe W. Targeting Pancreatic Cancer. Contemporary Oncology. Proceedings: 8th International Conference of Contemporary Oncology, Poznan, 16-18 March, 2016 19(Supplement 1), 2016.
31. Zielinski R, Skora S, Rusin A, Fokt I, Heimberger A, Sawaya R, Priebe W*. Combination of topoisomerase II poison Berubicin with STAT3 inhibitor WP1066 blocks potently tumor growth in GMB models. Proceedings: 20th Annual Society for Neuro-Oncology Annual Scientific Meeting, Nov 19-22, 2015; San Antonio, TX, 2015.
32. Conrad C, Fokt I, Madden T, Priebe W*. An anthracycline analog, WP744, purposely designed to circumvent the blood-brain barrier appears to show activity in patients with recurrent high-grade gliomas in a Phase I study. Proceedings: 2015 SNO-SCIDOT Joint Conference, Nov 2015; San Antonio, TX, 2015.
33. Hashimoto Y, Yaghi N, Wei J, Huang N, Ezhilarasan R, Kong L-Y, Zhou S, Chivukula P, Webb D, Priebe W, Payne J, Sulman E, Heimberger A. STAT3 inhibition enhances therapeutic efficacy of radiation treatment against established brain metastasis in murine melanoma model. Proceedings: 20th Annual Society for Neuro-Oncology Annual Scientific Meeting, Nov 19-22, 2015; San Antonio, TX, 2015.
34. Priebe W, Cybulski M, Fokt I, Conrad C,. Design and Development of Monosaccharide-based Anticancer Drugs. Proceedings: 58th Annual Scientific Meeting of the Polish Chemical Society, Sept 21-25, 2015, Gdansk, Poland:470, 2015.
35. Strozik T, Ozga M, Linke-Szewczyk A, Priebe W, Orlowski W, Derwinska K. Efficacy of 2-deoxy-D-glucose analog in glycolysis blocking in tumor cells. EJC -European journal of Cancer 51(Supplement 3):S5, 2015.
36. Zielinski R, Rusin A, Madden T, Conrad C, Johansen M, Fokt I, Skora S, Jayakumar A, Heimberger A, Priebe W*. Development of orally bioavailable formulation of WP1066 and its evaluation in vivo. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA; Cancer Res 2015 75(15 suppl), 2015.
37. Jayakumar A, Venugopal R, Zielinski R, Rusin A, Fokt I, Skora S, Ni X, Duvic M, Priebe W*. High sensitivity of cutaneous T-cell lymphoma (CTCL) to CABE, a component of propolis. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA; Cancer Res 2015 75(15 suppl), 2015.
38. Rusin A, Zielinski R, Fokt I, Nguyen V, Skora S, Jayakumar A, Priebe W*. WP760, A new highly potent and selective agent against melanoma including BRAFi resistant melanoma. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA; Cancer Res 2015 75(suppl 15), 2015.
39. Priebe W, Jayakumar A, Radjendirane V, Fleming J, Rusin A, Zielinski R, Skora S, Kang Y, Fokt I. Transcriptional control of pancreatic cancer and small molecule modulators of transcription. Proceedings of the EACR-AACR-SIC 2015 Special Conference, 20-23 June 2015; Florence, Italy, 2015.
40. Rusin A, Zielinski R, Fokt I, Nguyen V, Skora S, Jayakumar A, Priebe W*. Development of novel therapies against BRAFi resistant melanomas. Proceedings of the GAP 2015 Conference, 14-16 April, 2015; Houston, TX, 2015.
41. Kong L., Hatiboglu M., Wei J., Wang Y., McEnery K., Fuller G., Qiao W., Davies M., Priebe W., Heimberger A.. The Influence of the Tumor Microenviroment Expression of P-STAT3 on Therapeutic Efficacy: CNS Tumors Preferentially Impacted. 16th Annual Scientific Meeting of the Society of Neuro-Oncology, 2011.
42. Ahmed Ashour Ahmed, Juliet Goldsmith, Izabela Fokt, Xioo-Feng Le, Krystiana A. Krzysko, Bogdan Lesyng, Robert C Bast Jr., Priebe W. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemotherapy and Pharmacology, 2011.
43. Rudak I., Lewandowska H., Kalinowska M., Priebe W., Lewandowski W.. Anticancer properties of phenolic acids: cinnamic and bezoic acid derivatives. ESF-COST High-Level Research Conference, Systems Chemistry III, Crete, Greece, 2011.
44. Wei J, Kong L, Doucette T, Wang Y, Wu A, Fuller G, Rao G, Priebe W, Heimberger A.. Glioma-associated Cancer-initiating Cells Induce Immunosuppression. 242nd American Chemical Society National Meeting, 2011.
45. Priebe, W. The Importance of Entrepreneurial Scientist for the Future of the American Economy. SE/SW ACS Meeting, 2010.
46. Priebe W, Sun L, Fokt I, Zhang L, Jayakumar A, Zhang X, Madden T, Wang M. Berubicin, a topoisomerase II poison with high CNS uptake, potently inhibits cell growth and induces apoptosis in diffuse large B-cell lymphomas. 22nd EORTC – NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics Conference, Berlin, Germany 8(7):182, 2010.
47. Zhang L, Sun L, Qian J, Yang J, Priebe W, Yi Q, Wang M. Berubicin, a topoisomerase II poison with high CNS uptake, inhibits cell growth and induces apoptosis in diffuse large B-cell lymphomas. 22nd EORTC – NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics Conference, Berlin, Germany 8(7):180-181, 2010.
48. Wu A, Wei J, Kong Y, Priebe W, Sawaya R, Heimberger A. Glioma Cancer stem cells induce immune suppressive macrophages. 15th Annual SNO conference, Montreal, Canada, 2010.
49. Conrad C, Madden T, Ji Y, Colman H, Priebe W*. Berubicin: A novel anthracyline with high CNS uptake shows strong preclinical activity in both ependymoma cell lines and cancer stem-like cell line models. 15th Annual SNO conference, Montreal, Canada, 2010.
50. Emmett M, Wang X, Marshall A, Ji Y, Fokt I, Skora S, Conrad C, Priebe W*. 2-Deoxy-D-glucose inhibits n-glycosylation in glioblastoma-derived cancer stem cells. 15th Annual SNO conference, Montreal, Canada, 2010.
51. Kong LY, Doucette T, Wei J, Priebe W, Sawaya R, Yang J, Rao G, Heimberger A. Novel murine models of immune competent spontaneously-arising heterogeneous gliomas for evaluation the new classes of chemoimmunotherapies. 15th Annual SNO conference, Montreal, Canada, 2010.
52. Wang M, Sun L, Fokt I, Bao H, Zhang L, Jayakumar A, Priebe W*. Berubicin, a novel mechanistically altered anthracycline potently inhibits cell growth and induces apoptosis in mantle cell lymphoma. European Journal of Cancer Supplements 8(7):182, 2010.
53. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Sawaya R, Lang F, Heimberger A. Glioma cancer stems cells induce immune suppressive macrophages. 100th AACR Annual Meeting, Washington DC, 2010.
54. Priebe W. Glycolysis: Chemistry, Biology, and Therapeutic Ramification. 101st ACS Annual Meeting, San Francisco, CA, 2010.
55. Priebe, W. Jak2 Phosphorylates Tyr 177 of Bcr-Abl Activating the Ras and PI-3 Kinase Pathways and Maintains Functional Levels of Bcr-Abl in Chronic Myelogenous Leukemia. 51st ASH Annual Meeting and Exposition, 2009.
56. Madden T, Johansen MJ, Thapar J, Conrad C, Fokt I, Priebe W*. WP769, An orally bioavailable blood brain barrier penetrating anthracycline. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Boston, MA, 2009.
57. Priebe W, Cybulski C, Fokt I, Skora S, Conrad CA, Madden T. Blocking glycolysis with 2-deoxy-D-glucose prodrugs to target brain tumors: A novel concept. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Boston, MA, 2009.
58. Conrad C, Koul D, Guan S, Fokt I, Shen R, Ramnarian D, Madden T, Yung WKA, Atkinson J, Gilbertson R, Priebe W*. Berubicin: a novel topoisomerase II Inhibitor with activity in ependymoma. 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, New Orleans, 2009.
59. Kong LY, Wei J, Gelbard A, Wang T, Wei Q, Fokt I, Overwijk W, Priebe W, Heimberger A. STAT3 Blockade Enhances IFN-alpha Immunotherapy for Intracerebral Malignancy. Neuro-Oncology 11(5):615, 2009.
60. Koul D, Fokt I, Guan S, Conrad C, Madden T, Yang WK, Priebe W*. Berubicin: A Novel Topoisomerase II Inhibitor with Activity in Ependymoma. Neuro-Oncology 11(5):640, 2009.
61. Priebe, W. Drug discovery in academia: A chemist in the biologist's cookie jar. 238th ACS National Meeting, Wolfrom/Isbell/New Investigator Symposium, 2009.
62. Conrad C, Madden T, Sheng X, Priebe W*. Galectins and their role in high-grade glioma tumor progression. 238th ACS National Meeting, Wolfrom/Isbell/New Investigator Symposium, 2009.
63. Swiatek-Machado K, Ellert-Miklaszewska A, Szeja W, Priebe W, Grynkiewicz G, Lesyng B, Kaminska B. Evaluation of antitumor activity of novel inhibitors of JAK/STAT3 pathway in glimoa cells. 34th Congress of the Federation-of-European-Biochemical-Societies, FEBS Journal, Prage CZECH Republic 276:392-392, 2009.
64. Colman H, Conrad CC, Sai K, Wang S, Popoff S, Aldape K, Lang F, Fokt I, Madden TL, Yung WKA, Priebe W*. WP1193 inhibits JAK2/STAT3 pathway, blocks self-renewal and induces apoptosis in glioblastoma cancer stem cells. 100th American Association for Cancer Medicine Annual Meeting, 2009.
65. Rogers JC, Krastins B, Berry R, Priebe W, Dillon R, Sarracino D, Rosenblatt MM, Kilmer G, Dobbs M, Feather-Henigan K, Devakumar A, Major M, Kaboord BJ, Webb B, Lopez M, Nilsson CL, Lang FF, Colman HC, Conrad CA. Quantitative phosphoproteomic analysis of STAT3/IL-6/HIF1a signaling partners in NS11 glioblastoma stem cells with multiplexed tandem mass tags and a novel rapid Western blotting technique. 100th American Association for Cancer Research Annual Meeting, 2009.
66. Ahmed AA, Fokt I, Krzysko K, Lesyng B, Bast RC Jr, Priebe W*. Unsaturated glycoside of genistein induces severe microtubule depolymerization and mitotic arrest in ovarian cancer cells. 100th American Association for Cancer Research Annual Meeting, 2009.
67. Samanta A, Chakraborty S, Samanta S, Wang Y, Sun X, Schlette E, Priebe W, Arlinghaus R. Disruption of the Bcr-Abl/Jak2/HSP90 Network Complex Leading to Induction of Apoptosis in Drug-Resistant CML Cells by a New Compound WP1193. Blood 112(11):1098, 2008.
68. Antonovic L, Fokt I, Johansen MJ, Szymanski S, Skora S, Conrad CA, Madden T, Priebe W*. A novel monosaccharide-based antimetabolite 2,2-difluoro-D-glucose (2-DFG) blocks glycolysis and induces cell death in gliomas. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, 2008.
69. Kazerooni R, Conrad C, Johansen MJ, Sakamoto M, Fokt I, Schroeder C, Thapar N, Meyer C, Priebe W, Madden T. Hematologic pharmacodynamics linked to the pharmacokinetics of berubicin (B), a blood-brain barrier penetrating anthracycline active against high grade glioma, in phase 1/11 clinical trials. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland 6(12):187-188, 2008.
70. Heimberger AB, Kong L-Y, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Wei J, Qiao W, Schmittling RJ, Archer GE, Sampson JH, Hiraoka N, Priebe W, Fuller GN, Sawaya R. The Role of Tregs in Human Glioma Patients and their Inhibition with a Novel STAT-3 Inhibitor. 2008 Congress of Neurological Surgeons Annual Meeting, 2008.
71. Colman H, Sai K, Wang S, Popoff S, Aldape KD, Lang FF, Conrad CA, Madden T, Yung A, Priebe W*. Effect of a small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells. 2008 ASCO Annual Meeting, Chicago, IL, 2008.
72. Heimberger AB, Sun W, Kong L, Abou-Ghazal M, Wei J, Gumin J, Colman H, Priebe W, Lang FF. Glioblastoma multiforme stem cells mediate immune suppression that can be inhibited with JAK2/STAT3 Blockage. 2008 ASCO Annual Meeting, Chicago, IL, 2008.
73. Guha S, Chakraborty A, Kunnumakkara A, Szymanski S, Fokt I, Abbruzzese J, Aggarwal B, Madden T, Priebe W*. A novel JAK2-STAT3 inhibitor blocks mitogenesis and angiogenesis in pancreatic cancer. AACR Annual Meeting 2008, San Diego, CA, 2008.
74. Samanta AK, Chakroborty SN, Wang Y, Cortes J, Priebe W, Arlinghaus RB. Down-regulation of HSP90 expression by caffeic acid derivative WP1193 induced apoptosis in imatinib-sensitive/-resistant BCR-ABL+ cells by inducing degradation Bcr-Abl/Jak2 signaling proteins. AACR Annual Meeting 2008, San Diego, CA, 2008.
75. Conrad CA, Sheng X, Ji Y, Howard C, Emmett M, Lang F, Aldape K, Priebe W, Madden T, Nilsson C. Galectin-1 expression in glioblastoma cell lines is associated with p53 gene expression: Implications with cell survival, invasive phenotype, presence in CD133 glioma cancer-stem cells (CSC) and poor patient survival. AACR Annual Meeting 2008, 2008.
76. Priebe W, Madden T, Conrad CA. Berubicin, a Brain Tumor Targeting Anthracycline: Discovery and Clinical Evaluation. AACR Annual Meeting 2008, 2008.
77. Kazerooni R, Schroeder C, Conrad C, Johansen M, Sakamoto M, Fokt I, Thapar N, Meyer C, Priebe W, Madden T. Metabolite pharmacokinetics of berubicinol (BRB-ol), the 13-hydroxy metabolite of RTA744 (berubicin(BRB)), a blood-brain barrier penetrating anthracycline active against high grade glioma, in phase I/II clinical trials. AACR Annual Meeting 2008, 2008.
78. Kong LY, Abou-Ghazal MK, Chakraborty A, Fuller G, Madden T, Qiao W, Grimm EA, Priebe W, Heimberger AB. Small molecule inhibition of Stat3 enhances survival in mice with intracerebral melanoma. AACR Annual Meeting 2008, San Diego, CA, 2008.
79. Madden T, Xu QA, Thapar J, Johansen M, Priebe W, Kazerooni R. A new era of liquid chromatography: Immediate effects of high throughput analysis on drug development and therapeutic drug monitoring. PITTCON, 59th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, Louisiana, 2008.
80. Setny P, Lesyng B, Priebe W*. Modeling a Novel Binding Mode of JAK2 Substrate Competitive Inhibitors. Keystone Symposia on Molecular and Cellular Biology, Computer-Aided Drug Design, 2008.
81. Setny P, Lesyng B, Priebe W*. Modeling a Novel Binding Mode of JAK2 Substrate Competitive Inhibitors. Keystone Symposia on Molecular and Cellular Biology, Computer-Aided Drug Design, Santa Fe, New Mexico, 2008.
82. Jackson CBJ, Judd L, Menheniott T, Priebe W, Howlett M, Giraud A. A novel inhibitor of STAT3 as a therapeutic against augmented gp130 signaling in human gastric cancer. 20th Lorne Cancer Center Conference Proceedings:261, 2008.
83. Kazerooni R, Conrad C, Schroeder C, Johansen M, Sakamoto M, Thapar N, Meyer C, Priebe W, Madden I. Phase I clinical pharmacokinetics of RTA 744 (berubicin(B)), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 13-hydroxy metabolite, berubicinol (B-o1). Molecular Cancer Therapeutics, San Francisco, CA 6(12):3465S-3466S, Part 2, 2007.
84. Schroeder CP, Fokt I, Johansen M, Rhea R, Allen TL, Madden T, Priebe W*. WP760, a New DNA-binding agent with unique melanoma selectivity. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA 6(12):3407S-3407S, Part 2, 2007.
85. Colman H, Priebe W, Popoff S, Aldape K, Wang S, Conrad C, Lang F, Sai K, Yung A. Regulation of Glioblastoma Stem Cell Self-Renewal by Stat3, 2007.
86. Conrad C, Madden T, Maher E, Cloughesy T, Meyer C, Priebe W , Baud C, Fokt I, Gilbert M, Groves M, Levin V, Yung WKA. Preliminary Results of an Accelerated Dose Escalation Phase 1 Trial with the Novel Anthracycline Derivative (RTA 744) in Patients with Primary Brain Tumors. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, 2006.
87. Priebe W, Fokt I, Szymanski S, Bao J, Conrad C, Chakraborty A, Abbruzzese J, Guha S, Myers J, Madden T. Novel small molecule inhibitors of Jak2/STAT3 pathway: design, structure-activity relationship, and oral bioavailability. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, 2006.
88. Fokt I, Priebe W*. Synthesis of WP744/RTA744, a New Blood-Brain Barrier (BBB) Penetrating Anthracycline. 62nd SW ACS Regional Meeting, 2006.
89. Conrad, CA, Meyer C, Madden T, Priebe W, Lang FF. Survival study of RTA 744 (currently a single agent phase 1 study) along and in combination with temozolomide in orthotopic model of glioma. 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, J of Clinical Oncology 24(18S):1556, 2006.
90. Madden T, Kazerooni R, Myers J, Culotta K, Donato N, Johansen M, Kondo Y, Mack D, Priebe W*. The precilincal pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway. 97th AACR Annual Meeting 47, 2006.
91. Kupferman ME, Zhou G, Zhao M, Jasser S, Daka-Yazici Y, Priebe W, Myers J. A novel inhibitor of STAT3 signaling in Head and neck squamous cell carcinoma. 97th AACR Meeting 47, 2006.
92. Ferrajoli A, Faderl S,Wang T, Priebe W, Kantarjian H, Talpaz M, Estrov Z. WP1066: A Novel PI-3K Inhibitor with Antileukemic Activity in Philadelphia Chromosome-Positive ALL. Abstract 850, 47th Annual Meeting of American Society of Hematology, Atlanta, GA, 2005.
93. Kong L-Y, Kapuria V, Bartholomeusz G, Talpaz M, Priebe W, Donato NJ. Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. 47th Annual Meeting of American Society of Hematology, GA, Abstract 1489, 2005.
94. Bartholomeusz GA, Donato N, EstrovZ, Priebe W, Talpaz M. Activation of a Novel Proteasomal Independent Bcr/Abl Degradation Pathway by WP1130 Induces Apoptosis in CML Cells. 47th Annual Meeting of American Soc Hemat, Atlanta, GA, Abstract 2862, 2005.
95. Lee S, Fokt I, Grossman HB, Czerniak B, Dinney C, Priebe W*. WP744, a novel anthracycline highly active against wild-type and doxorubicin-resistant bladder cancer cell lines. Proc 96 Am Assoc Cancer Res, 46: 2389, 2005.
96. Fanale MA, Liu TS, McKenzie TS, Fokt I, Priebe W, Hunt KK. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. ASCO Annual Meet, Florida, 2005.
97. Fokt I, Conrad CA, Madden T, Priebe W, et al. The discovery and development of blood-brain barrier (BBB) penetrating anthracyclines for the treatment of brain tumors. Clinical Cancer Res11 (24): 9013S-9013S, 2005.
98. Thapar NC, Priebe W, Johansen MJ, et al. Summary of the preclinical pharmacology of RTA 744 (WP744): A new topo II inhibitor in phase I development. Clinical Cancer Res11 (24): 9019S-9020S, 2005.
99. Iwamaru A, Szymanski SP, Fokt I, Priebe W, et al. Inhibition of STAT3 signaling by WP1066, a novel tyrosine kinase inhibitor in malignant glioma cells in vitro and in vivo. Clinical Cancer Res 11 (24): 9021S-9021S, 2005.
100. Bao JJ, Fokt I, Szymanski S, Priebe W, et al. Inhibition of constitutively active STAT3 by WP1066 suppresses proliferation and induces apoptosis in pancreatic cancer cells. Clinical Cancer Res 11 (24): 9026S-9027S, 2005.
101. Priebe W, Skora S, Fokt I, Zielinski R, Jayakumar A, Venugopal R. Preparation of pyridylethenylamides as caffeic acid analogs for the treatment and prevention of. CAPLUS.
102. Joseph, W. G.; Michael, J. T.; Katherine, B.; Jeffrey, A. H.; Amy, C.; Justin, F.; Julia, A.; Henry, C.; Alain, B.; Saloni, S.; Christine, L.; JangKeun, K.; Jiwoon, P.; Cem, M.; Jonathan, F.; Christopher, M.; Yaron, B.; Stephanie, R.; Nusrat, J. E.; Brian, A.; Josh, C.; Mark, S.; David, T.; Timothy, B.; Clifton, D.; Mark, T. H.; Nathaniel, J. M.; Victoria, K. B.; Emily, A. M.; Sharon, A. T.-B.; Elizabeth, J. A.; Wes, A. S.; Rebekah, J. D.; Gabrielle, A. W.; Kevin, J.; Timmy, L.; Deborah, M.; Alessia, A.; Yentli Soto, A.; Arnold, O.; Zimu, C.; Joseph, D.; Waldemar, P.; Mark, R. E.; Sonja, M. B.; Maya Kelsey, J.; Nidia, S. T.; Kevin, B. C.; Victoria, Z.; Rob, M.; Peter, G.; Jonathan, C. S.; Pedro, M. M.-V.; Simon, P.; Christopher, E. M.; Eve Syrkin, W.; Deanne, T.; Robert, E. S.; Afshin, B.; Douglas, C. W.; Stephen, B. B.. Lethal COVID-19 Associates With RAAS-Induced Inflammation For Multiple Organ Damage Including Mediastinal Lymph Nodes. bioRxiv.

Book Chapters

1. Perez-Soler, R., Khokhar, A.R., Priebe, W., Krakoff, I.H.. Liposomes in Drug Delivery. In: Use of liposomes as carriers of lipophilic antitumor agents. 1st. Routledge: London, 1-9, 2017.
2. Debinski W, Priebe W, Tatter S. Maximizing Local Access to Therapeutic Deliveries in Glioblastoma. Part I: Targeted Cytotoxic Therapy. In: Glioblastoma. Part I: Targeted Cytotoxic Therapy. Codon Publications: Brisbane (Au), 2014.
3. Priebe W||, Fokt I, Grynkiewicz G. Glycal Derivatives, Synthesis and Chemical Reactions. In: Glycosicence - Chemistry and Chemical Biology. Frasier-Reid, Tatsuta, Thiem (Eds.): Poland, 1-38, 2007.